open access

Vol 3, No 1 (2000)
Basic sciences
Published online: 2000-02-25
Submitted: 2012-01-23
Get Citation

Identification of transplanted pancreatic islet cells by radioactive Dithizone-[131I]-Histamine conjugate. Preliminary report

Piotr Garnuszek, Iwona Licińska, Agnieszka Mrozek, Agata Wardawa, Piotr S. Fiedor, Aleksander P. Mazurek
Nucl. Med. Rev 2000;3(1):61-63.

open access

Vol 3, No 1 (2000)
Basic sciences
Published online: 2000-02-25
Submitted: 2012-01-23

Abstract

Background: The unique mechanism of dithizone action in the interior of the viable pancreatic islet suggests the possible development of a specific radiopharmaceutical that may have a potential clinical application in the diagnosis of the pancreatic organ allografts or islets rejection. The radiodiagnostic properties of the newly developed radioactive analogue of dithizone, i.e. Dithizone-[131I]-Histamine conjugate have been evaluated in the present study.
METHODS: The four islet cells transplantation models were chosen for this purpose.
The most important feature of the Dithizone-[131I]-Histamine conjugate is its possessed ability of zinc chelation. As was presented in the recent study, the conjugate stains pink-reddish the isolated pancreatic islets in vitro. Among the studied transplantation models, only the islets grafting under testis capsule enabled determination of the pancreatic islets in rats by radioactive Dithizone-[131I]-Histamine conjugate. The level of the radioactivity in the recipient testis (right) was almost two times higher compared to the controls (0.24 vs. 0.13% ID/g, respectively).
CONCLUSIONS:These preliminary data demonstrate the ability of the developed radioactive analogue of dithizone for in vivo identification of transplanted pancreatic islets, and suggests a potential clinical application of the radiodithizone in the diagnosis of the pancreatic islet rejection.

Abstract

Background: The unique mechanism of dithizone action in the interior of the viable pancreatic islet suggests the possible development of a specific radiopharmaceutical that may have a potential clinical application in the diagnosis of the pancreatic organ allografts or islets rejection. The radiodiagnostic properties of the newly developed radioactive analogue of dithizone, i.e. Dithizone-[131I]-Histamine conjugate have been evaluated in the present study.
METHODS: The four islet cells transplantation models were chosen for this purpose.
The most important feature of the Dithizone-[131I]-Histamine conjugate is its possessed ability of zinc chelation. As was presented in the recent study, the conjugate stains pink-reddish the isolated pancreatic islets in vitro. Among the studied transplantation models, only the islets grafting under testis capsule enabled determination of the pancreatic islets in rats by radioactive Dithizone-[131I]-Histamine conjugate. The level of the radioactivity in the recipient testis (right) was almost two times higher compared to the controls (0.24 vs. 0.13% ID/g, respectively).
CONCLUSIONS:These preliminary data demonstrate the ability of the developed radioactive analogue of dithizone for in vivo identification of transplanted pancreatic islets, and suggests a potential clinical application of the radiodithizone in the diagnosis of the pancreatic islet rejection.
Get Citation

Keywords

dithizone; iodine radioisotopes; pancreatic islet cells; transplantation; monitoring

About this article
Title

Identification of transplanted pancreatic islet cells by radioactive Dithizone-[131I]-Histamine conjugate. Preliminary report

Journal

Nuclear Medicine Review

Issue

Vol 3, No 1 (2000)

Pages

61-63

Published online

2000-02-25

Bibliographic record

Nucl. Med. Rev 2000;3(1):61-63.

Keywords

dithizone
iodine radioisotopes
pancreatic islet cells
transplantation
monitoring

Authors

Piotr Garnuszek
Iwona Licińska
Agnieszka Mrozek
Agata Wardawa
Piotr S. Fiedor
Aleksander P. Mazurek

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., Świętokrzyska 73 street, 80–180 Gdańsk, Poland

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail: viamedica@viamedica.pl